|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ChiCTR |
|
Last refreshed on:
|
18 April 2017 |
|
Main ID: |
ChiCTR-ICR-15007168 |
|
Date of registration:
|
2015-10-02 |
|
Prospective Registration:
|
Yes |
|
Primary sponsor: |
|
|
Public title:
|
Clinical efficacy of dexmedetomidine mixed with ropivacaine for analgesia effect of Ischemic disease of lower extremity
|
|
Scientific title:
|
Clinical efficacy of dexmedetomidine mixed with ropivacaine for analgesia effect of Ischemic disease of lower extremity |
|
Date of first enrolment:
|
2015-10-04 |
|
Target sample size:
|
Traditional drug group:30;ropivacaine group:30;Mixed Dexmedetomidine group:30; |
|
Recruitment status: |
Recruiting |
|
URL:
|
http://www.chictr.org.cn/showproj.aspx?proj=12054 |
|
Study type:
|
Interventional study |
|
Study design:
|
Randomized parallel controlled trial
|
|
Phase:
|
New Treatment Measure Clinical Study
|
|
|
Countries of recruitment
|
|
China
| | | | | | | |
|
Contacts
|
|
Name:
|
Shi Zhao
|
|
Address:
|
154 Anshan road, Tianjin
|
|
Telephone:
|
+86 13652021211 |
|
Email:
|
steermyship@aliyun.com |
|
Affiliation:
|
Tianjin Medical University General Hospital |
|
|
Name:
|
Wang Guo-lin
|
|
Address:
|
154 Anshan road, Tianjin
|
|
Telephone:
|
+86 15822855556 |
|
Email:
|
wang_guolin@hotmail.com |
|
Affiliation:
|
|
| |
|
Key inclusion & exclusion criteria
|
Inclusion criteria: 1. patients with lower limb ischemic disease treated by vascular surgery;
2. ASA grade II -III;
3. patients aged 65-85 years old, sex is not limited;
4. patients have fully understandthe nature of the study, voluntary participation in this experiment andsigned informed consent.
Exclusion criteria: 1. known to the study of the drug ingredients allergies andallergic constitution;
2. puncture site infection ulcer;
3. coronary heart disease; bronchial asthma; severe hypertension; heart andlung disease andliver andkidney function is not complete; serious blood system dysfunction;
4. obesity (BMI>30);
5. The history of nervous system disease, drug addiction andalcoholism;
6. Clinical trials of other drugs in the past 4 weeks;
7. compliance is poor, can not be completed by the research program;
8. for any reason, the researchers believe that there is any situation that is not suitable for inclusion.
Age minimum:
20
Age maximum:
85
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Ischemic disease of lower extremity
|
|
Intervention(s)
|
|
Traditional drug group:medication;ropivacaine group:adminstrated ropivacaine;Mixed Dexmedetomidine group:adminstrated ropivacaine with dexmedetomidine ;
|
|
Primary Outcome(s)
|
|
Visual Analogue Scale;
|
|
Source(s) of Monetary Support
|
|
self support
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|